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Plasma components: FFP, FP24, and
Thawed Plasma
A.F. EDER AND M.A. SEBOK
A rose is a rose, is a rose . . .GERTRUDE STEIN
Plasma intended for transfusion is separated from
whole blood or collected by apheresis procedures and
frozen according to specific requirements defined by
the method of preparation (Table 1).1–3 Fresh frozen
plasma (FFP) and plasma frozen within 24 hours of
phlebotomy (FP24) differ in the amount of time that is
allowed to elapse between collection and frozen storage,
which has practical ramifications not only for blood
establishments whose collection sites are geographically
remote from their manufacturing facilities but also for
transfusion services that are often asked about the
properties and proper handling of the differently labeled
plasma components.
With the time constraints imposed on producing
FFP, and the additional demand for plasma collected
from male donors for transfusion to mitigate the risk of
transfusion-related acute lung injury (TRALI), many
blood centers have increased production of FP24.
Despite the increasing or exclusive use of FP24 by many
hospitals in recent years, questions persist regarding its
use in clinical practice, perhaps reflecting deeply
ingrained practice or familiarity with FFP at some
hospitals, a belief that“fresh is better,”or concern about
the unfavorable past experiences with other plasma
components such as solvent-detergent (SD) plasma in
the United States. Although clinical trials have not been
performed to compare the efficacy of FP24 with that of
FFP, the available in vitro data on the concentration or
functional activity of coagulation factors in the plasma
components support the use of FP24 and Thawed
Plasma for the common and currently accepted
indications for plasma transfusion.
Description
FFP and FP24 are U.S.Food and DrugAdministration
(FDA)-licensed products as defined in 21 CFR 640.34(a)
and (b).3 FFP is prepared from a whole blood or
apheresis collection and frozen at –18°C or colder
within the time frame required for the anticoagulant or
collection process (Table 1). FFP derived from whole
blood in CPDA-1,CPD,and CP2D anticoagulant must be
separated and placed at –18°C within 8 hours of
collection. FFP from apheresis procedures is collected
in ACD or sodium citrate anticoagulant and must be
placed in the freezer within 6 to 8 hours according to
manufacturers’ instructions. Most apheresis collection
sets are closed or functionally closed systems,but some
are open systems, which affects the suitability of
converting apheresis FFP to Thawed Plasma (discussed
in greater detail in a later section). Licensed FP24 can
only be prepared from whole blood and must be placed
at –18°C within 24 hours after phlebotomy. The FDA
has not yet approved using plasma collected by
apheresis procedures for FP24.
The FDA has no finished product quality control
requirements for FFP or FP24, provided that the manu-
facturing, transporting, and storage specifications for
time and temperature are met. International standards
for final product specifications for frozen plasma
components differ. The Council of Europe guidelines
specify FFP as being frozen within 8 hours of
phlebotomy to –70°C and containing more than 0.70
IU/mL (70%) factor VIII (FVIII) activity. In contrast, the
United Kingdom Blood Transfusion Service no longer
defines the interval between collection and storage for
frozen plasma,provided the quality control specification
is achieved.4,5 The requirement for standard UK FFP is
at least 75 percent of the units contain more than 70
IU/mL of FVIII.4,5 Interestingly, lower clotting factor
activity (> 50 IU/mL) is accepted for the SD-treated FFP
commercially available in Europe,which implicitly sets
the lower limit of the normal range as a minimal,
clinically acceptable standard that most of the units
produced should meet.
As reviewed herein, the vast majority of units of FFP
and FP24 contain levels of all clotting factors and
inhibitor activity that are above the lower limit of the
normal range (≥ 0.50 IU/mL or 50% factor activity) at
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expiration, suggesting that additional quality control
specifications are unnecessary and unwarranted.
Labeling and Managing FFP and FP24 After
Thawing
After being thawed and stored at 1° to 6°C for 24
hours, plasma can no longer be labeled as FFP or FP24,
but most units can be converted to Thawed Plasma.6
First introduced in the 17th edition of AABB Standards,
the expiration dating on Thawed Plasma was extended
from 24 hours to 5 days. Thawed Plasma is derived from
either FP24 or FFP that has been prepared in a closed
system and can be stored for up to 5 days at 1° to 6°C.2
After the 24-hour expiration for FP24 or FFP,the original
license number on the unit should be removed and the
product relabeled asThawed Plasma. Alternatively,FP24
or FFP can be relabeled asThawed Plasma once thawed
and placed at 1° to 6°C, rather than waiting until
expiration.
Some hospitals, especially trauma centers,maintain
an inventory of Thawed Plasma to avoid the delays in
plasma delivery to patients associated with thawing FFP
or FP24. Because Thawed Plasma currently has a
maximum shelf life of 5 days after the initial thawing,
the benefit of maintaining a quickly accessible inventory
to treat trauma cases must be weighed against the
possible increase in outdating of thawed units.
Managing a Thawed Plasma inventory also requires
knowledge of the method of collection used by the
blood supplier for FFP. Some apheresis collection sets
are open systems (e.g., Baxter Auto-C;Table 1), and the
resultant FFP cannot be converted to Thawed Plasma
and has only a 24-hour shelf life after thawing. Because
the same product code may be used by blood suppliers
for FFP collected from apheresis both in a closed system
and in an open system, hospitals must determine from
the supplier the method of collection used when the
hospitals are creatingThawed Plasma from FFP with the
Table 1. Plasma component
Component Preparation Expiration*
FFP Whole blood collection Separated from whole Frozen state: 12 months stored at ≤ –18°C
blood collected in CPD, After thawing: 24 hours, stored at 1°–6°C
Prod.Code: CP2D,CPDA-1 and placed






FFP Apheresis Placed at –18°C or below Frozen state: 12 months stored at ≤ –18°C
within 6 or 8 hours After thawing: 24 hours, stored at 1°–6°C
Prod.Code: according to instructions
18211 for storage bags. FFP, if prepared from open system apheresis collection sets, cannot be





FP24 Whole blood collection Separated from whole Frozen state: 12 months stored at ≤ –18°C
blood and placed at –18°C After thawing: 24 hours, stored at 1°–6°C
Prod.Code: or below within 24 hours.






Thawed Plasma FFP (prepared in closed After the initial 24-hour 5 days from date original product was thawed; stored at 1°–6°C
system) or FP24 postthaw period, store at
1°–6°C FFP, if prepared from open system apheresis collection sets, cannot be
converted toThawed Plasma after 24 hours (seeThawed Plasma)
Closed collection system:Baxter (Amicus;Alyx);COBE/Gambro
(Spectra;Trima,TrimaACCEL;Haemonetics MCS+ LN8150 and LN9000)
Open collection system:Baxter Auto-C,Haemonetic PCSA/PCS2,Model
V-50 and Model 30 systems; some kits on Fenwal
*AABB Standards. [FDA has stated:“After thawing: 6 hours [21CFR606.122(m)] or 24 hours if approved for alternative procedure under 21.CFR640.120.”]
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intent to possibly store the Thawed Plasma for more
than 24 hours. This obstacle will be eliminated with the
implementation of ISBT 128, because the method of
collection will be evident in the labeling of the unit of
FFP (Table 1). Licensed FP24 is currently only prepared
from whole blood collections and not apheresis
procedures, so there are no special considerations in
converting units toThawed Plasma.
Indications for Plasma Transfusion
Plasma transfusion is indicated to treat preoperative
or bleeding patients who require replacement of
multiple plasma coagulation factors, such as patients
with liver disease or disseminated intravascular coagu-
lation (DIC). Acquired coagulation factor deficiencies
may also result from massive transfusion through
dilution or warfarin therapy, which decreases the
vitamin K–dependent factors (FII, FVII, FIX, FX, protein
C, protein S). Plasma transfusion may be indicated to
reverse the effect of warfarin in bleeding patients or
patients at significant risk of bleeding during invasive
procedures whenever time does not permit reversal of
warfarin anticoagulation with vitamin K administration.
Finally, plasma is often lifesaving for patients with
thrombotic thrombocytopenic purpura (TTP) who are
deficient in ADAMTS13 (von Willebrand factor [vWF]–
cleaving protease) activity. As contraindications,FFP and
FP24 should never be given to FVIII–deficient patients,
or any patient with known hereditary coagulation
deficiencies for whom specific clotting factor
concentrates are available. An international registry of
commercially available clotting factor concentrates is
maintained by the International Society onThrombosis
and Hemostasis.7
In a population of healthy adults,plasma coagulation
factor and inhibitor activity occur within a wide
reference range (0.50–1.50 U/mL; 50–150% factor
activity), reflecting normal biologic variability. The
heterogeneity observed for some clotting factors is
linked to blood group and race. Plasma collected from
group O individuals contains less vWF and FVIII than
plasma collected from group A individuals, and
Caucasians generally have lower levels than African
Americans.8 This interindividual variability should be
taken into account when evaluating the factor activity in
plasma components collected from healthy volunteer
blood donors. For example, a unit of FP24 collected
from a groupA individual could have more vWF:VIIIC at
expiration than a unit of FFP prepared from a group O
individual; yet both products are clinically acceptable.
Many patients who require plasma transfusion have
normal or high levels of FVIII, because it is an acute
phase protein and is often increased by liver disease and
other common inflammatory diseases. Individual
coagulation proteins and inhibitors also demonstrate
maturation during infancy and childhood, with most
factors reaching adult levels by 6 months of age in both
term and preterm infants.9,10 Notably, the level of FVIII
at birth is the same as for an adult, even in premature
infants, but the vitamin K–dependent factors and
coagulation inhibitors fall below the lower limit of the
reference range for adults. Despite these differences,
healthy infants are not coagulopathic, and the levels
reflect the normal hemostatic balance for the
developmental stage. Consequently, the same consider-
ations apply to infants being given plasma transfusion
for acquired multiple coagulation factor deficiencies and
related clinical indications as for adults.
Plasma transfusion is typically given as 10 to 20
mL/kg and expected to deliver a hemostatic dose of
coagulation factors and inhibitors. The minimum levels
of coagulation factors required to maintain hemostasis
(e.g., 50 mg/dL fibrinogen; 15–30 % factor activity) are
about 3- to 10-fold below the amount normally present
in healthy adults. Plasma containing physiologic
amounts (e.g.,≥ 0.50 IU/mL) of coagulation proteins will
increase deficient clotting factor activity to at least 30
percent in patients with acquired coagulopathy when
dosed appropriately. The biologic variability that is
observed in the normal content of plasma products does
not affect the clinical effectiveness of the product.
Similarly, FFP, FP24, and Thawed Plasma used at 5 days
retain sufficient functional content during production
and storage to deliver a hemostatic dose that is expected
to correct acquired coagulation defects.11–17
Functional Content of Plasma Components
The relative functional protein content of FFP,FP24,
and Thawed Plasma is affected by the method of
preparation, temperature, and duration of storage. The
2002 Circular of Information states that FP24 contains
reduced amounts of FV compared with FFP, but several
studies have demonstrated minimal or no reductions in
the levels of FV and other plasma clotting factors and
inhibitors,with the exception of FVIII,which is reduced
by 16 to 24 percent (Table 2). The 2002 Circular of
Information is currently under revision and is expected
to clarify this point.
FV and FVIII in plasma or whole blood are retained
to variable degrees in different studies under the
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conditions used to prepare FFP and FP24 (Table 2).
Smith et al.11 compared the effect of extending the
storage time from 8 hours to 24 hours on the level of
labile coagulation factors in plasma derived from CPD-
whole blood held at 1° to 6°C. Their results showed no
significant changes in FV, vWF:Ag, FIX, and ristocetin
activity at the different times,but there was a statistically
significant decrease (16%) in FVIII activity at 24 hours
compared with 8 hours. The level of FVIII activity,
however, at 24 hours (76%) was still above the lower
limit of the reference range. O’Neill et al.12 evaluated
the coagulation activity in whole blood stored for 24
hours at 4°C before separation into plasma. At expira-
tion after thawing (24 hours),FP24 contained an average
of 64 percent FVIII activity, whereas FFP contained an
average of 84 percent, a reduction of 24 percent.
Cardigan et al.13 also evaluated coagulation factor
activity in whole blood stored overnight (18–24 hours)
at 4°C before separation into plasma, and likewise
observed a 23 percent reduction in FVIIIC,but reported
that the vast majority of units (98%) were within the
same range as for 8-hour plasma (0.40 to 1.60 IU/mL).
The activity of coagulation factors inThawed Plasma
from FFP is stable for 5 days at 1° to 6°C,except for FVIII
which is reduced by 35 to 41 percent at expiration.14
Thawed Plasma on day 5 had on average 41 to 63
percent FVIII activity,depending onABO blood group.14
The relative amounts of coagulation factor and inhibitor
activity inThawed Plasma on day 5 prepared fromwhole
blood or apheresis collections compared with FFP are
shown in Table 3. Plasma collected by apheresis has
slightly higher factor levels than plasma prepared from
whole blood collection, likely because of less
anticoagulant dilution, lower citrate concentrations,
earlier mean freezing times,or differences in laboratory
assays.15 This tendency,however,may explain the lower
observed decreases in factor activity with Thawed
Plasma prepared from apheresis FFP compared with
whole blood FFP.15
The factor content ofThawed Plasma prepared from
FP24 throughout the 5-day storage period has not been
reported, although Nifong et al.18 measured the
coagulant activity in thawed FP24 stored under less
Table 2. Effect of FFP and FP24 processing conditions on FV and FVIII activity
Mean (%) Mean % % units in FFP
Factor n (SD or 2 SD range) n (SD or 2 SD range) reference range Reference
FV 10 98.6 (3.2) 10 101.4 (2.5) NR 11
10 102 (15) 100 (14) – 12
66 94 (35–148) 60 80 (53–112) 100 13
FVIII:C 10 89.8 (1.9) 10 75.9 (2.4) – 11
10 84 (16) 10 64 (13) – 12
66 100 (48–185) 60 77 (38–140) 98 13
vWF activity 10 103.3 (18.1) 95.0 (13.2) 11
– – – – – 12
66 101 (57–163) 60 97 (30–185) 87 13
SD = standard deviation
FFP conditions 8 hours, 4°C FP24 conditions 24 hours, 4°C
Table 3. Relative factor activity in FP24,Thawed Plasma, and SD plasma





blood FFP), FFP), SD-
FP24 day 5† day 5† plasma‡
Reference [13] [12] [11] [14] [15] [19]
Fibrinogen 12 6 – 0 2 –
FV 15 2 +3 16 9 9
FVII +6 5 – 20 4 –
FVIII 23 24 15 41 (groupA,O) 14 20
35 (group B)
FIX +7 – +11 – – 3
FX +18 0 – 6 0 –
FXI 7 – – – 0 17
vWF activity 4 – 8 – – 6
Protein C 2 3 – – – 11
(U/dL)
Protein S 8 1 – – – 51
(U/dL)
ATIII 1 0 – – – 9
α2-Antiplasmin 5 – – – – 76
(plasmin
inhibitor)
ADAMTS13 – – – – – 0
activity
ADAMTS13 10 11 – –
activity * [Ref 16]
*Differences are expressed as a percentage decrease or increase (+) in mean factor
activity compared with FFP or other standard, as indicated; (–), not reported.
†Day 5 compared with day 1
‡SD, solvent/detergent-treated plasma, compared with untreated plasma
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favorable conditions (i.e., 20°C rather than 1° to 6°C).
The average FVIII activity measured in 15 units of FP24
stored at 20°C was 59 percent on day 5, which was
decreased by 34 percent compared with the activity on
day 1 of storage, but was still within the normal
reference range for human plasma.
Scott et al.16 compared the ADAMTS13 activity in
therapeutic plasma components used in the treatment
ofTTP (Table 3). FP24 and FFP as well asThawed Plasma
at 5 days all had equivalent ADAMTS13 activity, which
was stable under the different processing and storage
conditions.
In summary, the levels of coagulation factors and
inhibitors in FP24 are minimally or not different
compared with those of FFP,with the exception of FVIII,
which is variably reduced by about 16 to 23 percent.
For comparison, the functional effect of solvent-
detergent treatment on plasma is included in Table 3
because of the striking difference in anticoagulant
proteins in SD plasma compared with FP24 and FFP.18,19
The SD process reduces transmission of lipid-enveloped
viruses but also adversely affects the amount of protein
S and plasmin inhibitor in the final product, causing a
51 percent and 76 percent loss in activity,respectively.19
The reduced coagulation factor and inhibitor levels did
not impair efficacy of SD-plasma in clinical studies, but
likely accounted for the uncommon but serious adverse
events associated with its use.20–25 Thrombotic
complications in several patients with TTP undergoing
plasma exchange with SD-plasma were attributed to
depletion of protein S; excessive bleeding and
fibrinolytic complications described in patients
undergoing liver transplant were attributed to lower
levels of plasmin inhibitor in the group treated with SD-
plasma compared with FFP.22,24,25 In the United States,
SD-plasma was linked to the deaths of six patients who
experienced thrombotic events or excessive bleeding
during orthotopic liver transplantation.23 SD-plasma is
no longer commercially available in the United States,
but is presently an approved product in Europe for all of
the same indications as FFP (Octaplas, Octapharma,
Vienna,Austria). Interestingly, the risk of TRALI may be
potentially lower for SD-plasma than for FFP and FP24
because it is prepared from pools of plasma from 500
to 1600 donors, although a difference has not been
substantiated.
In conclusion,FFP,FP24,andThawed Plasma can be
safely used to effectively treat the coagulopathy of liver
disease,TTP, and DIC, to reverse the effect of warfarin,
and to manage massive traumatic blood loss.Most units
of FFP and FP24 contain coagulation factor activity
within the normal reference range, and even Thawed
Plasma on day 5 retains sufficient levels of coagulation
factor activity to deliver a hemostatic dose of all factors
except, in some cases, FVIII. Being an acute phase
protein,however,FVIII is not deficient in many patients
who are candidates for plasma transfusion. If there is
clinical concern about the relative degree of FVIII
deficiency in the setting of multiple clotting factor
deficits, the use of Thawed Plasma should be carefully
considered or its use should be limited to the first few
days of storage.14 In contrast, Bostrom et al.26 have
proposed extending storage of Thawed Plasma to 14
days for clinical use, despite the observed mean 25
percent and 50 percent decrease in FV and FVIII levels,
respectively.
Utilization Trends in the United States
In the United States, the use of FFP and FP24 has
changed with time and varies across the country. A
recent review of monthly transfusable plasma shipments
to hospital customers by theAmerican Red Cross (ARC)
from July 1, 2005, to March 31, 2007, showed a shift in
the percentage of hospital customers using predom-
inantly (defined as > 80% of the plasma distributed to
the hospital) FP24 from 31 percent of hospital
customers in the second half of 2005 to 45 percent of
hospital customers in the first quarter of 2007 (Fig. 1).
Conversely, the percentage of hospital customers using
predominantly FFP decreased from 59 percent in the
second half of 2005, to only 40 percent in the first
quarter of 2007 (Fig. 1).
In addition to a progressive shift in overall
distributions from FFP to FP24, the number of
geographic regions using predominantly FP24 increased
63 percent in this time period. By March 2007, FP24
accounted for more than 90 percent of the transfusable
plasma shipments in 13 of the 35 ARC regions. These
regions represented shipments to 657 hospitals in 23
Fig. 1. Shift in transfusable plasma shipment types.
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states and the District of Columbia in March 2007. The
percentage of hospitals using any FP24 increased from
52 percent to 69 percent; in contrast, the percentage of
hospitals transfusing exclusively FFP decreased from 48
percent to 31 percent during the study period (Table 4).
The temporal trends in plasma component use in
the community indicate the general acceptance of the
therapeutic equivalence of FP24 and FFP for most
indications, as supported by the in vitro studies of
functional coagulation activity and protein levels in
plasma components. Thawed Plasma is not an FDA-
licensed plasma component,and the extent of its use in
the community has not been assessed.
Audits of Plasma Use in the United States
The United States transfuses far more plasma than
European countries,both on a per capita basis and when
normalized for RBC use.27,28 The United States was
second only to Germany in the per capita usage of FFP
among seven European countries in one survey,27,28 and
the ratio of FFP to RBC use in the United States was 1:3.6
compared with 1:6.0 in Europe.28
Audits of transfusion practice inAmerican hospitals
have demonstrated the overuse and misuse of plasma.
Dzik and Rao29 evaluated the usage of FFP at
Massachusetts General Hospital for 3 months in 2003,
and found that 31 percent of the orders for FFP were to
correct an abnormal coagulation test result (i.e.,
international normalized ratio [INR]) before an invasive
procedure. Several studies have shown, however, that
plasma transfusion does not correct mildly elevated
coagulation tests most of the time,and the preoperative
prothrombin time to INR values do not predict
postsurgical bleeding.30,31 Given the risks associated
with plasma transfusion, includingTRALI, as well as the
cost of maintaining a safe and adequate supply of
transfusable plasma, the AABB recently emphasized the
importance of appropriate evidence-based hemothera-
py practices to minimize unnecessary transfusion.32
Clinical trials have been initiated to better define
appropriate plasma transfusion practice.33
Conclusions
The levels of coagulation factors and inhibitors in
FP24 are minimally or not different when compared
with FFP,with the exception of FVIII,which is variably
reduced by about 16 to 23 percent but remains above
the lower limit of the reference range in most units.
Thawed Plasma throughout the 5-day storage period has
progressive and more pronounced loss of FVIII activity,
and decreased levels of all other factors except
fibrinogen, yet still retains sufficient factor activity for
clinical use. FFP and FP24 are considered by many to
be therapeutically equivalent choices for the common
and accepted indications for plasma transfusion.
Thawed Plasma prepared either from FFP (if collected in
a closed system) or from FP24 is also an acceptable
component to treat patient coagulopathy of liver
disease, TTP, and DIC and to reverse the effect of
warfarin when clinically indicated.
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